BeiGene
BGNE
£139.36
Share price
0.49%
Change (1 day)
25.34%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Earnings for BeiGene (BGNE)
Earnings in 2024 (TTM): -£0.69 Billion
According to BeiGene 's latest financial reports the company's current earnings are £3.31 Billion. In 2023 the company made an earning of -£0.92 Billion, an increase over its 2022 earnings that were of -£1.36 Billion. The earnings displayed on this page is the company's Pretax Income.
Earnings history for BeiGene from 2015 to 2024
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2024 (TTM)  | -£0.69 Billion | -25.07% |
| 2023 | -£0.92 Billion | -32.52% |
| 2022 | -£1.36 Billion | 24.39% |
| 2021 | -£1.09 Billion | -13.21% |
| 2020 | -£1.26 Billion | 72.69% |
| 2019 | -£0.73 Billion | 36.01% |
| 2018 | -£0.54 Billion | 616.83% |
| 2017 | -£74.29 Million | -15.24% |
| 2016 | -£87.65 Million | 107.91% |
| 2015 | -£42.16 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 | -£13.7 Million | -97.92% | 🇺🇸 USA |
 | -£7.82 Million | -98.81% | 🇺🇸 USA |